Genosco reports Phase I/II data for EGFR TKI in NSCLC

Genosco (Cambridge, Mass.) reported data from 91 evaluable non-small cell lung cancer (NSCLC) patients in a Phase I/II trial showing that once-daily oral YH25448 (GNS-1480) led to an objective response rate (ORR) of 64%. YH25448 was generally well tolerated with no dose-limiting toxicities (DLTs) reported. The open-label, South Korean trial enrolled patients with EGFR mutation-positive advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKIs) with or without brain metastases. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago...